Capricor Therapeutics (CAPR) has an average rating of buy and mean price target of $45.20, according to analysts polled by FactSet.
What else is happening in Research?
Research
UBS Upgrades Cameco to Buy From Neutral, CA$166 Price Target
UBS Upgrades Cameco to Buy From Neutral, CA$166 Price Target
$CCJ
Research
BofA Securities Initiates Coverage on Clean Harbors With Buy Rating, $360 Price Target
Clean Harbors (CLH) has an average rating of overweight and mean price target of $332.07, according to analysts polled by FactSet.Price: $302.77, Change: $-0.98, Percent Change: -0.32%
$CLH
Research
RBC Raises Price Target on Tenet Healthcare to $283 From $236, Keeps Outperform Rating
Tenet Healthcare (THC) has an average rating of buy and mean price target of $255, according to analysts polled by FactSet.
$THC